<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Radical cystectomy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Radical cystectomy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Radical cystectomy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Monish Aron, MD, MCh, FRCS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Seth P Lerner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The clinical spectrum of urothelial bladder cancer ranges from non-muscle-invasive to metastatic disease at presentation. The most important treatment-related issues include the identification of those who can be adequately managed without total cystectomy, those who need radical cystectomy, and those who require a combined modality approach that may include chemotherapy and/or radiation therapy.</p><p>Radical cystectomy is the treatment of choice for nonmetastatic muscle-invasive bladder cancer and remains the standard by which other treatments are judged. It also has a role in carefully selected patients with non-muscle-invasive disease as well as in patients with locally advanced or metastatic bladder cancer who achieve a major clinical response to cisplatin-based chemotherapy.</p><p>The indications, techniques, and outcomes of radical cystectomy are reviewed here. Other treatments of bladder cancer are discussed in these other topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2978.html" rel="external">"Overview of the initial approach and management of urothelial bladder cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/98344.html" rel="external">"Bladder preservation treatment options for muscle-invasive urothelial bladder cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2996.html" rel="external">"Treatment of primary non-muscle invasive urothelial bladder cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/98347.html" rel="external">"Management of recurrent or persistent non-muscle invasive bladder cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2991.html" rel="external">"Neoadjuvant treatment options for muscle-invasive urothelial bladder cancer"</a> and  <a class="medical medical_review" href="/z/d/html/2966.html" rel="external">"Adjuvant therapy for muscle-invasive urothelial carcinoma of the bladder"</a>.)</p><p></p><p class="headingAnchor" id="H3075692045"><span class="h1">INDICATIONS</span></p><p class="headingAnchor" id="H1642616183"><span class="h2">Muscle-invasive bladder cancer</span><span class="headingEndMark"> — </span>The general approach to initial therapy for muscle-invasive bladder cancer is presented in this algorithm  (<a class="graphic graphic_algorithm graphicRef113732" href="/z/d/graphic/113732.html" rel="external">algorithm 1</a>) and discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2978.html" rel="external">"Overview of the initial approach and management of urothelial bladder cancer", section on 'Muscle invasive disease'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Radical cystectomy is indicated for patients with T2 to T4a, M0, muscle-invasive bladder cancer who are surgical candidates and are willing to accept urinary diversion. Eligible patients typically receive cisplatin-based neoadjuvant chemotherapy, but not radiation therapy, prior to cystectomy. (See  <a class="medical medical_review" href="/z/d/html/2991.html" rel="external">"Neoadjuvant treatment options for muscle-invasive urothelial bladder cancer", section on 'Radical cystectomy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Salvage radical cystectomy may be indicated for initially inoperable patients (clinical stage T4b and/or bulky clinical stage N1 to 3) who are rendered resectable following a favorable response to chemotherapy. </p><p></p><p class="headingAnchor" id="H954593478"><span class="h2">Non-muscle-invasive bladder cancer</span></p><p class="bulletIndent1"><span class="glyph">●</span>Although the standard approach for high-grade non-muscle-invasive bladder cancer (Ta, T1, carcinoma in situ [Tis]  (<a class="graphic graphic_table graphicRef110763" href="/z/d/graphic/110763.html" rel="external">table 1</a>)) is transurethral resection followed by intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), radical cystectomy may be indicated for patients who either have very high-risk features or persistent/recurrent disease despite less invasive therapy. (See  <a class="medical medical_review" href="/z/d/html/2978.html" rel="external">"Overview of the initial approach and management of urothelial bladder cancer", section on 'Indications for cystectomy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other less common indications for radical cystectomy in patients without muscle-invasive bladder cancer include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diffuse, Ta low-grade bladder cancer that is not amenable to complete transurethral resection. (See  <a class="medical medical_review" href="/z/d/html/2967.html" rel="external">"Pathology of bladder neoplasms", section on 'Papillary lesions'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bladder cancers that cause symptoms (eg, hemorrhage, urinary frequency) that cannot be managed endoscopically or medically.</p><p></p><p class="headingAnchor" id="H545732391"><span class="h1">SURGICAL STEPS</span><span class="headingEndMark"> — </span>Radical cystectomy entails removal of the bladder along with the organs at highest risk of harboring tumors that extend beyond the bladder and regional pelvic lymph nodes [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H3362297804"><span class="h2">Cystectomy</span><span class="headingEndMark"> — </span>Surgery can be performed with an open or minimally invasive transperitoneal approach by surgeons experienced with these techniques  (<a class="graphic graphic_figure graphicRef55963" href="/z/d/graphic/55963.html" rel="external">figure 1</a>). The ureters are identified at the pelvic brim and mobilized down to and divided just above the ureterovesical junction. A terminal ureteral biopsy may be sent for frozen section analysis to rule out carcinoma in situ. The bladder is then progressively freed from surrounding structures, beginning posteriorly, proceeding laterally, and then anteriorly, including transection of the urethra. A urethrectomy should be performed for men who have invasive cancer at the apical urethral margin of resection [<a href="#rid2">2</a>] and in women not undergoing reconstruction with a neobladder in order to reduce the likelihood of a positive surgical margin or tumor recurrence. (See <a class="local">'Urethral recurrence after radical cystectomy'</a> below.)</p><p>The need to resect organs adjacent to the bladder differs between sexes. Because sexual dysfunction is a known complication of pelvic surgery, sexual-preserving techniques of radical cystectomy have been developed for both males and females. Such techniques should be offered to those who are motivated to preserve sexual function as the majority of patients will benefit [<a href="#rid3">3</a>]. </p><p class="headingAnchor" id="H4144827656"><span class="h3">Men</span><span class="headingEndMark"> — </span>In men, standard radical cystectomy generally includes removal of the prostate, seminal vesicles, distal ureters, and regional lymph nodes. This frequently results in damage to the neurovascular bundles, thus causing impotence. Men with good erectile function who desire to preserve their potency after radical cystectomy may be candidates for preservation of the cavernous nerves similar to that performed during nerve-sparing radical prostatectomy. (See  <a class="medical medical_review" href="/z/d/html/6944.html" rel="external">"Radical prostatectomy for localized prostate cancer", section on 'Nerve-sparing approach'</a>.)</p><p>Four neurovascular bundle-sparing techniques have been described for men: </p><p class="bulletIndent1"><span class="glyph">●</span>Prostate and seminal vesicle sparing</p><p class="bulletIndent1"><span class="glyph">●</span>Prostate capsule sparing</p><p class="bulletIndent1"><span class="glyph">●</span>Seminal vesicle sparing</p><p class="bulletIndent1"><span class="glyph">●</span>Nerve sparing</p><p></p><p>In a 2017 systematic review, these four techniques were associated with superior postoperative potency rate but comparable local and distant recurrence and overall and disease-free survival rates compared with standard radical cystectomy at intermediate (three to five years) follow-up [<a href="#rid4">4</a>]. There was no superiority of any one technique [<a href="#rid5">5,6</a>]. Thus, the choice of techniques can be by surgeon preference. </p><p>However, nerve-sparing cystectomy requires dissection close to the urinary bladder, exposing patients to the risks of positive soft tissue surgical margins. Thus, candidates for nerve-sparing cystectomy should be carefully selected based on the following criteria [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Organ-confined disease</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of tumor at the levels of the prostate, prostatic urethra, and bladder neck</p><p></p><p>Erections sufficient for intercourse are reported in 31 to 50 percent of patients within one to two years after nerve-sparing cystectomy, although most patients require assistance with phosphodiesterase-5 inhibitors, such as <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>, <a class="drug drug_general" data-topicid="10172" href="/z/d/drug information/10172.html" rel="external">vardenafil</a>, or <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a> [<a href="#rid7">7-9</a>]. </p><p class="headingAnchor" id="H202525505"><span class="h3">Women</span><span class="headingEndMark"> — </span>In women, standard radical cystectomy, also known as anterior exenteration, includes removal of the bladder, entire urethra and adjacent vagina, uterus, distal ureters, and regional lymph nodes. Given that involvement of the female reproductive organs (ie, uterus, cervix, ovaries, and vagina) is not common [<a href="#rid10">10</a>], pelvic organ-preserving techniques can be applied in women to preserve the neurovascular bundle, vagina, uterus, and/or ovaries [<a href="#rid3">3</a>].</p><p>A 2017 systematic review of women undergoing radical cystectomy with orthotopic neobladder reconstruction concluded that a pelvic-organ-sparing approach is oncologically sound and functionally superior to the standard technique, albeit based on low-quality retrospective evidence [<a href="#rid11">11</a>]. However, women undergoing such a procedure should have [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Organ-confined disease</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of tumor at the levels of the urethra and bladder neck</p><p></p><p>In addition, women with a family history of breast or ovarian cancer should undergo bilateral salpingo-oophorectomy. (See  <a class="medical medical_review" href="/z/d/html/3250.html" rel="external">"Risk-reducing salpingo-oophorectomy in patients at high risk of epithelial ovarian and fallopian tube cancer"</a>.)</p><p class="headingAnchor" id="H3076076704"><span class="h2">Lymphadenectomy</span><span class="headingEndMark"> — </span>The extent of pelvic lymph node dissection is defined anatomically by primary and secondary nodal drainage of the bladder. With radical cystectomy, all patients should undergo at least a standard bilateral pelvic lymphadenectomy, which includes the external and internal iliac and obturator nodes, with removal of a minimum of 12 lymph nodes [<a href="#rid12">12</a>]. (See <a class="local">'Prognostic factors for survival'</a> below.)</p><p>Some evidence suggests that an extended lymph node dissection may be beneficial at the time of radical cystectomy [<a href="#rid13">13,14</a>]. The extended template includes the presacral and common iliac lymph nodes up to the aortic bifurcation and may include removal of the retroperitoneal lymph node proximal to the aortic bifurcation to the level of the inferior mesenteric artery (superextended lymph node dissection). </p><p>However, two randomized trials failed to show an oncologic (survival) benefit with an extended lymph node dissection:</p><p class="bulletIndent1"><span class="glyph">●</span>The Association of Urologic Oncology AB25/02 randomized phase III trial of extended versus standard pelvic lymph node dissection failed to show a significant impact of the former on recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) in 401 patients with cT1-4aN0M0 urothelial carcinoma of the bladder who had not received prior chemotherapy [<a href="#rid15">15</a>]. The impact of this trial on contemporary practice is limited by the exclusion of neoadjuvant chemotherapy and the relatively low use of adjuvant chemotherapy for eligible patients (58 of 205 [28 percent]). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A more contemporary trial, SWOG S1011, has been presented orally at the 2023 American Society of Clinical Oncology annual meeting. Six hundred eighteen patients with cT2-4a N0-2 bladder cancer underwent radical cystectomy with standard or extended lymphadenectomy and were followed for six years [<a href="#rid16">16</a>]. Although more lymph nodes were removed with extended compared with standard lymphadenectomy (median 39 versus 25), there was no difference in nodal metastasis rate (26 versus 24 percent), and both disease-free survival and overall survival were similar. Extended lymphadenectomy was also associated with more severe complications (16 versus 8 percent) and more deaths within 90 days (19 versus 7 patients). </p><p></p><p>These two randomized phase III trials clearly establish that an extended node dissection does not provide any benefit for patients undergoing a radical cystectomy for clinical stage cT2-4aN0-2 muscle-invasive predominant urothelial bladder cancer and that a bilateral standard node dissection should be the standard of care moving forward. </p><p class="headingAnchor" id="H778992388"><span class="h2">Urinary diversion</span><span class="headingEndMark"> — </span>Removal of the bladder requires that the urinary flow be redirected, which may result in either a noncontinent or continent diversion. The choice of urinary diversion is based upon patient and surgeon preference and may be influenced by the extent of cancer and other patient-related factors. These options and the issues involved in choosing an approach for an individual patient are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2958.html" rel="external">"Urinary diversion and reconstruction following cystectomy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SURGICAL APPROACHES</span><span class="headingEndMark"> — </span>Radical cystectomy can be performed open or with one of the minimally invasive techniques (laparoscopic or robotic). The goal of minimally invasive radical cystectomy is to reproduce the oncologic results of an open procedure while minimizing surgical complications and postoperative recovery time. The techniques of minimally invasive radical cystectomy continue to evolve. Our preference is to use the robotic technique, although the choice of approach should be based on patient and tumor factors as well as the surgeon's expertise and experience. </p><p class="headingAnchor" id="H371505127"><span class="h2">Open</span><span class="headingEndMark"> — </span>Traditionally, radical cystectomy has been performed using an open approach that allows wide excision of the bladder, extended lymph node dissection, and a full range of urinary diversion. </p><p class="headingAnchor" id="H3160794932"><span class="h2">Laparoscopic</span><span class="headingEndMark"> — </span>Laparoscopy was first used for removal of the urinary bladder in 1992 [<a href="#rid17">17</a>], and subsequent advances have evolved toward a robotic-assisted intracorporeal approach to include extended lymph node dissection and totally intracorporeal urinary diversion.</p><p>Between 1999 and 2006, the authors performed laparoscopic radical cystectomy in 54 patients for bladder cancer [<a href="#rid18">18</a>]. Of these, 17 underwent a totally laparoscopic approach for the cystectomy and urinary diversion, while 37 underwent laparoscopic cystectomy, followed by the urinary diversion procedure (ileal conduit or orthotopic neobladder) through a mini-laparotomy open incision. The lower rate of perioperative complications in the open-assisted group led us to discontinue a totally laparoscopic approach. Major complications associated with a totally laparoscopic approach include bowel leak and/or urine extravasation and sepsis. However, advances in robotic technology and techniques have led to a resurgence of a purely intracorporeal minimally invasive approach to radical cystectomy.</p><p class="headingAnchor" id="H1456375"><span class="h2">Robot-assisted</span><span class="headingEndMark"> — </span>Robot-assisted radical cystectomy has evolved from, and further extended, the purely laparoscopic approach and has steadily increased in popularity among urologists who are familiar with robotic techniques. Robotic technology aids complex laparoscopic surgery due to three-dimensional visualization and wristed, articulating instruments, which facilitate intracorporeal suturing. According to National Inpatient Sample (2008–2014) data, robot-assisted radical cystectomy utilization increased from 12.2 percent in 2011 to 22.8 percent in 2014 [<a href="#rid19">19</a>]. </p><p>At the author's institution, robot-assisted radical cystectomy comprised 40 percent of all radical cystectomies [<a href="#rid20">20</a>]. Following robot-assisted radical cystectomy and high-extended bilateral lymphadenectomy, we now perform completely intracorporeal urinary diversion (instead of using a mini-laparotomy). Complication rates and oncologic outcomes of robot-assisted radical cystectomy are similar to those cited for open techniques. (See <a class="local">'Open versus minimally invasive approach'</a> below.) </p><p>While the most common urinary diversions performed after robotic radical cystectomy have been an ileal conduit or an ileal orthotopic neobladder, we have added robotic continent cutaneous diversions to our reconstructive armamentarium as well [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/2958.html" rel="external">"Urinary diversion and reconstruction following cystectomy"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">OUTCOMES</span></p><p class="headingAnchor" id="H2031521708"><span class="h2">Operative morbidity and mortality</span><span class="headingEndMark"> — </span>Patients with muscle-invasive bladder cancer typically are older and frequently have substantial comorbidities. The median age in large series ranges from 63 to 67 years, with approximately 5 percent over 80 years [<a href="#rid22">22,23</a>]. Furthermore, 34 to 50 percent are classified as high perioperative risk on the basis of an American Society of Anesthesiologists score of 3 or greater  (<a class="graphic graphic_table graphicRef87504" href="/z/d/graphic/87504.html" rel="external">table 2</a>) [<a href="#rid24">24-26</a>]. </p><p>Improvements in surgical technique and perioperative care have reduced the morbidity and mortality of radical cystectomy, although short-term complications and perioperative mortality are reported in 30 to 70 percent and 0.8 to 3 percent of patients, respectively, in single-institution and population-based studies [<a href="#rid27">27-30</a>]. The frequency of complications and mortality appears to be related to surgeon experience and hospital volume as well as the age and medical comorbidities of the patient [<a href="#rid31">31</a>]. </p><p>The most common causes of major complications include cardiovascular diseases, septic complications from urine or bowel leak, wound dehiscence, pulmonary embolus, and hemorrhage [<a href="#rid32">32</a>]. Common late (&gt;90 day) complications include ventral hernia, calculus formation, ureteroenteric stricture, and parastomal hernia in all patients, as well as loss of kidney function and B12 deficiency in those over 70 [<a href="#rid33">33</a>]. </p><p class="headingAnchor" id="H601457440"><span class="h2">Prognostic factors for survival</span></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor stage is among the most important factors for predicting both relapse and survival following radical cystectomy. In the absence of neoadjuvant chemotherapy, the outcomes following radical cystectomy correlate with the extent of local invasion and with the presence or absence of lymph node involvement [<a href="#rid34">34-41</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Approximately 50 to 60 percent of patients with invasive bladder cancer (clinical stage T2 to T4a) have organ-confined disease without lymph node involvement (pathologic stage pTis to T2, pN0). In this group, long-term survival is reported in 75 to 85 percent of cases.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In 20 to 30 percent of cases, local extension into the perivesical fat (pT3a to b) and/or adjacent pelvic viscera (pT4a) will be present in the cystectomy specimen without lymph node disease (N0). Long-term survival in this setting is approximately 45 to 55 percent of these patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In 20 to 30 percent of patients, regional lymph node metastasis (pTany, pN1 to 3) is identified, and this is associated with a substantially poorer prognosis, with 25 to 35 percent of patients remaining disease free. However, the survival of node-positive patients also depends on the T stage. As an example, pT2N1 patients have a 50 percent five-year survival probability. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neoadjuvant or adjuvant therapy – Neoadjuvant chemotherapy results in a lower risk of recurrence and an improvement in overall survival compared with surgery alone. For patients who receive neoadjuvant chemotherapy, the post-chemotherapy extent of residual local disease is also strongly associated with survival, with those patients achieving a complete pathological response (no residual tumor within the bladder and lymph nodes) having the most favorable prognosis. (See  <a class="medical medical_review" href="/z/d/html/2991.html" rel="external">"Neoadjuvant treatment options for muscle-invasive urothelial bladder cancer"</a>.)</p><p></p><p class="bulletIndent1">For patients in whom neoadjuvant chemotherapy was not administered, consideration of adjuvant chemotherapy is reasonable based on risk of recurrence and prognosis. (See  <a class="medical medical_review" href="/z/d/html/2966.html" rel="external">"Adjuvant therapy for muscle-invasive urothelial carcinoma of the bladder"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical factors – Achieving negative surgical margins and removing sufficient lymph nodes have been associated with improved survival and local recurrence rate after adjustment for pathologic factors and neoadjuvant chemotherapy usage by multivariate analysis [<a href="#rid42">42</a>]. Surgeon experience also impacts patient outcomes. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgical margin – A 2017 meta-analysis of 36 studies associated a positive surgical margin with poorer survival after radical cystectomy for bladder cancer [<a href="#rid43">43</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lymph node count – Removal of &gt;10 lymph nodes was associated with increased overall survival (hazard ratio 0.52, 95% CI 0.43-0.64) [<a href="#rid44">44</a>]. Hospitals that achieve high lymph node counts tend to have higher survival rates after radical cystectomy for bladder cancer [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgeon experience – Surgeon experience and institutional volume strongly predict favorable outcomes for either open or robotic techniques [<a href="#rid46">46</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor factors:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lymphovascular invasion – Lymphatic or vascular invasion is an independent predictor of progression in T1 and muscle-invasive, node-negative bladder cancer in several cohorts [<a href="#rid47">47-49</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extracapsular extension of lymph node metastasis – On multivariate analysis, extracapsular extension of lymph node metastases is a strong prognostic factor [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Molecular markers – Molecular markers, such as p53, p21, p27kip1, pRB, and p16, are independent predictors of post-cystectomy survival in several series [<a href="#rid51">51-54</a>]. Multiple studies have suggested that panels of such markers may be better at predicting recurrence and/or survival following initial treatment [<a href="#rid54">54-56</a>]. However, these markers are not routinely evaluated in cystectomy specimens and require further validation before they can be adopted for routine use [<a href="#rid57">57</a>].</p><p></p><p class="headingAnchor" id="H3929680730"><span class="h2">Urethral recurrence after radical cystectomy</span><span class="headingEndMark"> — </span>Second primary urothelial carcinoma in the urethra following radical cystectomy is uncommon (0.8 to 13.7 percent; average 4.6 percent). Male patients treated with non-orthotopic neobladder diversion as well as patients with prostatic involvement and tumor multifocality seem to be at the highest risk of urethral recurrence after radical cystectomy [<a href="#rid58">58</a>]. Incidence is also increased for patients with pathologic locally advanced or node metastatic cancer. </p><p>Urethral recurrence following radical cystectomy and orthotopic urinary diversion in women is rare but aggressive. Solitary and noninvasive recurrences have a favorable prognosis; however, invasive disease is associated with dismal prognosis, with a median survival of only six months [<a href="#rid59">59,60</a>]. (See  <a class="medical medical_review" href="/z/d/html/2958.html" rel="external">"Urinary diversion and reconstruction following cystectomy", section on 'Recurrent urothelial cancer'</a>.)</p><p>Patients with urethral recurrence have a five-year disease-free survival from 47 to 63 percent and an overall survival from 40 to 74 percent [<a href="#rid58">58</a>]. Treatment depends on stage and the presence of distant metastasis and is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3000.html" rel="external">"Treatment of metastatic urothelial carcinoma of the bladder and urinary tract"</a>.)</p><p class="headingAnchor" id="H2782988595"><span class="h2">Open versus minimally invasive approach</span><span class="headingEndMark"> — </span>Robot-assisted radical cystectomy is most often compared with open radical cystectomy. There is a reasonable amount of data on short-term, perioperative outcomes, but data on long-term oncologic outcomes are more limited. </p><p class="headingAnchor" id="H2399925700"><span class="h3">Perioperative</span><span class="headingEndMark"> — </span>A number of randomized trials comparing robot-assisted radical cystectomy with open radical cystectomy have been published [<a href="#rid61">61-65</a>]. Two 2019 meta-analyses (one of them a Cochrane review) of 540 participants in five randomized trials showed that robot-assisted cystectomy decreases the risk of perioperative blood transfusion (relative risk [RR] 0.58, 95% CI 0.43-0.80) and marginally decreases length of stay (RR -0.63 days, 95% CI -1.21 to -0.05) but is associated with a longer operative time (mean difference 68.51 minutes, 95% CI 30.55-105.48) compared with open radical cystectomy [<a href="#rid66">66</a>]. Otherwise, the two techniques have similar outcomes with regards to time to recurrence, rates of major complications, quality of life, and positive margin rates [<a href="#rid67">67</a>]. </p><p>However, most of the randomized trials comparing robot-assisted radical cystectomy with open radical cystectomy have used an open, rather than intracorporeal, approach to urinary diversion [<a href="#rid61">61-64</a>]. Complications from a radical cystectomy are more often directly, or indirectly, related to urinary diversion, and this was performed open in earlier randomized trials.</p><p class="bulletIndent1"><span class="glyph">●</span>In the first randomized trial comparing open and robot-assisted radical cystectomy with totally intracorporeal urinary diversion [<a href="#rid68">68</a>], the overall perioperative transfusion rate was lower in patients treated by robotic compared with open surgery (22 versus 41 percent). Other short-term outcomes, such as perioperative complications, hospital stay, and six-month health-related quality of life, were largely comparable between groups. Oncologic and functional outcomes will be assessed at longer follow-up. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another randomized trial that included 317 of 338 randomized patients who underwent radical cystectomy, robot-assisted radical cystectomy with intracorporeal urinary diversion resulted in fewer thromboembolic complications (1.9 versus 8.3 percent) and wound complications (5.6 versus 16.0 percent) than open radical cystectomy [<a href="#rid69">69</a>]. Patients undergoing robotic cystectomy reported greater quality of life and less disability at 5 and 12 weeks, but not after 12 weeks. Robotic surgery also resulted in two more median days alive and out of the hospital within 90 days of surgery (82 versus 80), a difference that was statistically significant but of uncertain clinical importance.</p><p></p><p>A retrospective review from the International Robotic Cystectomy Consortium database evaluated the outcomes of patients undergoing robot-assisted radical cystectomy with an extracorporeal versus intracorporeal diversion [<a href="#rid70">70</a>]. The intracorporeal group demonstrated a significantly lower rate of overall complications, gastrointestinal complications, and 30 and 90 day readmission rates. There were no differences in reoperation rates or operative times [<a href="#rid70">70</a>]. This retrospective review provided an initial insight into the potential benefits of intracorporeal diversion.</p><p>Another single-center retrospective study of 948 patients compared the outcomes of open cystectomy and robot-assisted cystectomy with intracorporeal diversion or extracorporeal diversion. The authors found that robotic cystectomy with intracorporeal diversion was associated with less blood loss, shorter hospitalization, lower ileus rate, and lower 30 and 90 day major complication rates [<a href="#rid71">71</a>]. </p><p>Due to the cost of the robot, disposables, and annual maintenance contract, direct costs are higher for robot-assisted radical cystectomy [<a href="#rid72">72</a>]; however, there is some suggestion that lower hospital costs associated with shorter length of stay and fewer complications may compensate [<a href="#rid73">73-75</a>]. A population-based study reported that overall cost differences between robot-assisted radical cystectomy and open radical cystectomy are not different for high-volume surgeons (&gt;7 per year) and high-volume hospitals (&gt;19 per year) [<a href="#rid76">76</a>]. These authors estimated that if the length of stay could be reduced to no more than seven days, which is achievable using enhanced recovery pathways, then robot-assisted radical cystectomy may be cost effective, particularly for high-volume centers [<a href="#rid76">76</a>]. </p><p class="headingAnchor" id="H5"><span class="h3">Oncologic</span><span class="headingEndMark"> — </span>Survival data are available for oncologic outcomes following laparoscopic/robotic cystectomy [<a href="#rid77">77-81</a>]. There appear to be no significant differences for a laparoscopic/robotic approach compared with the open approach. However, high-quality data are limited.</p><p>The larger series with longer follow-ups are retrospective and therefore should be interpreted with caution. </p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of the International Robotic Cystectomy Consortium database evaluated the long-term oncologic outcomes of 702 patients who underwent robot-assisted radical cystectomy with a median follow-up of 67 months (interquartile range [IQR] 18 to 84 months). Five-year disease-specific survival, cancer-specific survival, and overall survival (OS) were 67, 75, and 50 percent, respectively [<a href="#rid81">81</a>]. Surgical margins were positive in 8 percent of patients. The median lymph node yield was 16. Non-organ-confined disease and positive surgical margins were associated with poorer survival. These data are limited by a mix of retrospective and prospective data and no open comparison set. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another retrospective review from the Mayo Clinic Arizona with a median follow-up of 66 months found similar recurrence-free survival (RFS), OS, and recurrence patterns among 203 patients who underwent robot-assisted radical cystectomy and 278 patients who underwent open surgery. Patients who underwent robot-assisted cystectomy had a 5 and 10 year RFS of 71 and 70 percent and a 5 and 10 year OS of 59 and 40 percent, respectively, which are not statistically different from those who underwent open surgery [<a href="#rid82">82</a>]. </p><p></p><p>Several randomized trials provided prospective data on survival and cancer recurrence. Unfortunately, most of them are either by design underpowered to detect a small difference in oncologic outcomes or limited in the duration of follow-up. </p><p class="bulletIndent1"><span class="glyph">●</span>A report provided an update on secondary outcomes (oncologic) of an earlier randomized trial that was powered to detect a difference in 90 day complication rate between robot-assisted and open radical cystectomy as the primary outcome [<a href="#rid64">64</a>]. Since this trial was completed in 2013, the authors now have a median follow-up of 4.9 years (IQR 3.9 to 5.9) in 118 patients. The secondary outcomes analyzed were recurrence-free, cancer-specific, and overall survival. No differences were seen in recurrence (p = 0.4), cancer-specific survival (p = 0.4), or OS (p = 0.8). However, the pattern of first recurrence demonstrated a nonstatistically significant increase in distant metastatic events for those undergoing open radical cystectomy and a greater number of local/abdominal sites in the patients who underwent robotic surgery. The major limitation is that the trial was not powered to detect differences in cancer recurrence or survival outcomes [<a href="#rid83">83</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another update on an earlier trial (CORAL) also found similar five-year survival among patients who underwent open, laparoscopic, or robotic radical cystectomy [<a href="#rid84">84,85</a>]. Similarly, however, that trial was also not sufficiently powered to detect survival differences.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The largest multicenter randomized trial to date (RAZOR trial) was a randomized phase III noninferiority trial with a primary endpoint of two-year progression-free survival. A total of 302 patients (150 in the robot-assisted group and 152 in the open group) were analyzed, the majority with organ-confined disease. The two-year progression-free survival was 72.3 percent in the robotic arm and 71.6 percent in the open cystectomy arm (difference 0.7 percent, 95% CI -9.6 to 10.9 percent, p noninferiority = 0.001), thus indicating that robotic cystectomy was noninferior to open cystectomy for progression-free survival at two years [<a href="#rid65">65</a>]. </p><p></p><p class="headingAnchor" id="H3114234793"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116783.html" rel="external">"Society guideline links: Laparoscopic and robotic surgery"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/122007.html" rel="external">"Society guideline links: Bladder cancer"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/138541.html" rel="external">"Society guideline links: Cystectomy"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> for radical cystectomy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Muscle-invasive bladder cancer (see <a class="local">'Muscle-invasive bladder cancer'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Treatment of choice for T2-T4a, M0 bladder cancer</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Salvage therapy for T4b or N1-3 bulky nodal diseases that respond to chemotherapy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Non-muscle-invasive bladder cancer refractory to less invasive therapy (see <a class="local">'Non-muscle-invasive bladder cancer'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Diseases with very-high-risk features</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Persistent or recurrent disease</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Diffuse, Ta low-grade bladder cancer</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Intractable symptoms such as bleeding or urinary frequency</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical steps</strong> for radical cystectomy (see <a class="local">'Surgical steps'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cystectomy</strong> – Removal of the bladder (cystectomy) along with the organs at highest risk of harboring tumors that extend beyond the bladder and regional pelvic lymph nodes. (See <a class="local">'Cystectomy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In men, the prostate and seminal vesicles are also removed. In selected patients, nerve-sparing cystectomy may be performed to preserve potency if it does not compromise oncologic control. (See <a class="local">'Men'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For women, some of the female reproductive organs (ie, uterus, cervix, ovaries, and vagina) may be removed to achieve complete resection, but pelvic-organ-preserving techniques should be applied when feasible. (See <a class="local">'Women'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lymphadenectomy</strong> – For patients undergoing radical cystectomy for predominant urothelial muscle-invasive bladder cancer, we suggest a bilateral standard lymphadenectomy rather than an extended lymphadenectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Standard lymphadenectomy requires removal of a minimum of 12 external iliac, internal iliac, or obturator nodes. (See <a class="local">'Lymphadenectomy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Urinary diversion</strong> – Removal of the bladder requires that the urinary flow be redirected, which may result in either a noncontinent or continent diversion. (See  <a class="medical medical_review" href="/z/d/html/2958.html" rel="external">"Urinary diversion and reconstruction following cystectomy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical approaches</strong> – Radical cystectomy can be performed <strong>open</strong> or with one of the minimally invasive approaches (<strong>laparoscopic</strong> or <strong>robotic</strong>). Our preference is to use the robotic technique, although the choice of approach should be based on patient and tumor factors as well as the surgeon's expertise and experience. (See <a class="local">'Surgical approaches'</a> above.)</p><p></p><p class="headingAnchor" id="H39706711"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Andrew J Stephenson, MD, and Inderbir S Gill, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chang SS, Bochner BH, Chou R, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol 2017; 198:552.</a></li><li><a class="nounderline abstract_t">Laukhtina E, Rajwa P, Mori K, et al. Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. Eur Urol Focus 2022; 8:752.</a></li><li><a class="nounderline abstract_t">Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 2021; 79:82.</a></li><li><a class="nounderline abstract_t">Hernández V, Espinos EL, Dunn J, et al. Oncological and functional outcomes of sexual function-preserving cystectomy compared with standard radical cystectomy in men: A systematic review. Urol Oncol 2017; 35:539.e17.</a></li><li><a class="nounderline abstract_t">Jacobs BL, Daignault S, Lee CT, et al. Prostate capsule sparing versus nerve sparing radical cystectomy for bladder cancer: results of a randomized, controlled trial. J Urol 2015; 193:64.</a></li><li><a class="nounderline abstract_t">Colombo R, Pellucchi F, Moschini M, et al. Fifteen-year single-centre experience with three different surgical procedures of nerve-sparing cystectomy in selected organ-confined bladder cancer patients. World J Urol 2015; 33:1389.</a></li><li><a class="nounderline abstract_t">Schoenberg MP, Walsh PC, Breazeale DR, et al. Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup. J Urol 1996; 155:490.</a></li><li><a class="nounderline abstract_t">Kessler TM, Burkhard FC, Perimenis P, et al. Attempted nerve sparing surgery and age have a significant effect on urinary continence and erectile function after radical cystoprostatectomy and ileal orthotopic bladder substitution. J Urol 2004; 172:1323.</a></li><li><a class="nounderline abstract_t">Zippe CD, Raina R, Massanyi EZ, et al. Sexual function after male radical cystectomy in a sexually active population. Urology 2004; 64:682.</a></li><li><a class="nounderline abstract_t">Bree KK, Hensley PJ, Westerman ME, et al. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. J Urol 2021; 206:577.</a></li><li><a class="nounderline abstract_t">Veskimäe E, Neuzillet Y, Rouanne M, et al. Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. BJU Int 2017; 120:12.</a></li><li class="breakAll">AJCC Cancer Staging Manual, 8th ed, Amin MB, Edge S, Greene F, et al (Eds), Springer International Publishing, 2017.</li><li><a class="nounderline abstract_t">Perera M, McGrath S, Sengupta S, et al. Pelvic lymph node dissection during radical cystectomy for muscle-invasive bladder cancer. Nat Rev Urol 2018; 15:686.</a></li><li><a class="nounderline abstract_t">Bruins HM, Veskimae E, Hernandez V, et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. Eur Urol 2014; 66:1065.</a></li><li><a class="nounderline abstract_t">Gschwend JE, Heck MM, Lehmann J, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol 2019; 75:604.</a></li><li><a class="nounderline abstract_t">Lerner SP, Tangen C, Svatek RS, et al. SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer. J Clin Oncol 2023; 41:16 suppl.</a></li><li><a class="nounderline abstract_t">Parra RO, Andrus CH, Jones JP, Boullier JA. Laparoscopic cystectomy: initial report on a new treatment for the retained bladder. J Urol 1992; 148:1140.</a></li><li><a class="nounderline abstract_t">Haber GP, Campbell SC, Colombo JR Jr, et al. Perioperative outcomes with laparoscopic radical cystectomy: "pure laparoscopic" and "open-assisted laparoscopic" approaches. Urology 2007; 70:910.</a></li><li><a class="nounderline abstract_t">Harb-De la Rosa A, Garcia-Castaneda J, Hsu CH, et al. Perioperative outcomes of open vs. robotic radical cystectomy: a nationwide comparative analysis (2008-2014). Cent European J Urol 2020; 73:427.</a></li><li><a class="nounderline abstract_t">Mitra AP, Cai J, Miranda G, et al. Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases. J Urol 2022; 207:302.</a></li><li><a class="nounderline abstract_t">Desai MM, Simone G, de Castro Abreu AL, et al. Robotic Intracorporeal Continent Cutaneous Diversion. J Urol 2017.</a></li><li><a class="nounderline abstract_t">Stroumbakis N, Herr HW, Cookson MS, Fair WR. Radical cystectomy in the octogenarian. J Urol 1997; 158:2113.</a></li><li><a class="nounderline abstract_t">Clark PE, Stein JP, Groshen SG, et al. Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer 2005; 104:36.</a></li><li><a class="nounderline abstract_t">Koppie TM, Vickers AJ, Vora K, et al. Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer 2006; 107:2368.</a></li><li><a class="nounderline abstract_t">Chang SS, Cookson MS, Baumgartner RG, et al. Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol 2002; 167:2012.</a></li><li><a class="nounderline abstract_t">Cookson MS, Chang SS, Wells N, et al. Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol 2003; 169:101.</a></li><li><a class="nounderline abstract_t">Novara G, Catto JW, Wilson T, et al. Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy. Eur Urol 2015; 67:376.</a></li><li><a class="nounderline abstract_t">Aminoltejari K, Black PC. Radical cystectomy: a review of techniques, developments and controversies. Transl Androl Urol 2020; 9:3073.</a></li><li><a class="nounderline abstract_t">Lauridsen SV, Tønnesen H, Jensen BT, et al. Complications and health-related quality of life after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis of four RCTs. Syst Rev 2017; 6:150.</a></li><li><a class="nounderline abstract_t">Takada N, Abe T, Shinohara N, et al. Peri-operative morbidity and mortality related to radical cystectomy: a multi-institutional retrospective study in Japan. BJU Int 2012; 110:E756.</a></li><li><a class="nounderline abstract_t">Jerlström T, Gårdmark T, Carringer M, et al. Urinary bladder cancer treated with radical cystectomy: perioperative parameters and early complications prospectively registered in a national population-based database. Scand J Urol 2014; 48:334.</a></li><li><a class="nounderline abstract_t">Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009; 55:164.</a></li><li><a class="nounderline abstract_t">Knap MM, Lundbeck F, Overgaard J. Early and late treatment-related morbidity following radical cystectomy. Scand J Urol Nephrol 2004; 38:153.</a></li><li><a class="nounderline abstract_t">Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003; 21:690.</a></li><li><a class="nounderline abstract_t">Palapattu GS, Shariat SF, Karakiewicz PI, et al. Cancer specific outcomes in patients with pT0 disease following radical cystectomy. J Urol 2006; 175:1645.</a></li><li><a class="nounderline abstract_t">Mitra AP, Quinn DI, Dorff TB, et al. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int 2012; 109:846.</a></li><li><a class="nounderline abstract_t">Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19:666.</a></li><li><a class="nounderline abstract_t">Hautmann RE, Gschwend JE, de Petriconi RC, et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006; 176:486.</a></li><li><a class="nounderline abstract_t">Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176:2414.</a></li><li><a class="nounderline abstract_t">Tilki D, Svatek RS, Karakiewicz PI, et al. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol 2010; 183:87.</a></li><li><a class="nounderline abstract_t">Tilki D, Svatek RS, Novara G, et al. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol 2010; 184:888.</a></li><li><a class="nounderline abstract_t">Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004; 22:2781.</a></li><li><a class="nounderline abstract_t">Hong X, Li T, Ling F, et al. Impact of surgical margin status on the outcome of bladder cancer treated by radical cystectomy: a meta-analysis. Oncotarget 2017; 8:17258.</a></li><li><a class="nounderline abstract_t">Wright JL, Lin DW, Porter MP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 2008; 112:2401.</a></li><li><a class="nounderline abstract_t">Hollenbeck BK, Ye Z, Wong SL, et al. Hospital lymph node counts and survival after radical cystectomy. Cancer 2008; 112:806.</a></li><li><a class="nounderline abstract_t">Wilson TG, Guru K, Rosen RC, et al. Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. Eur Urol 2015; 67:363.</a></li><li><a class="nounderline abstract_t">Karakiewicz PI, Shariat SF, Palapattu GS, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006; 176:1354.</a></li><li><a class="nounderline abstract_t">Canter D, Guzzo T, Resnick M, et al. The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis. BJU Int 2008; 102:952.</a></li><li><a class="nounderline abstract_t">Bolenz C, Herrmann E, Bastian PJ, et al. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int 2010; 106:493.</a></li><li><a class="nounderline abstract_t">Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol 2005; 23:2358.</a></li><li><a class="nounderline abstract_t">Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22:1007.</a></li><li><a class="nounderline abstract_t">Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004; 22:1014.</a></li><li><a class="nounderline abstract_t">Shariat SF, Lotan Y, Karakiewicz PI, et al. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol 2009; 182:907.</a></li><li><a class="nounderline abstract_t">Youssef RF, von Rundstedt FC, Kapur P, et al. Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for squamous cell carcinoma. J Urol 2015; 193:451.</a></li><li><a class="nounderline abstract_t">Shariat SF, Bolenz C, Godoy G, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009; 182:78.</a></li><li><a class="nounderline abstract_t">Mitra AP, Pagliarulo V, Yang D, et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 2009; 27:3929.</a></li><li><a class="nounderline abstract_t">Goebell PJ, Groshen SL, Schmitz-Dräger BJ. Guidelines for development of diagnostic markers in bladder cancer. World J Urol 2008; 26:5.</a></li><li><a class="nounderline abstract_t">Laukhtina E, Mori K, D Andrea D, et al. Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis. Urol Oncol 2021; 39:806.</a></li><li><a class="nounderline abstract_t">Hrbáček J, Macek P, Ali-El-Dein B, et al. Treatment and outcomes of urethral recurrence of urinary bladder cancer in women after radical cystectomy and orthotopic neobladder: a series of 12 cases. Urol Int 2015; 94:45.</a></li><li><a class="nounderline abstract_t">Stein JP, Hertz J, Nichols PW. Urethral recurrence in a woman after continent orthotopic urinary diversion for bladder cancer. Urology 2008; 71:755.e1.</a></li><li><a class="nounderline abstract_t">Nix J, Smith A, Kurpad R, et al. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur Urol 2010; 57:196.</a></li><li><a class="nounderline abstract_t">Parekh DJ, Messer J, Fitzgerald J, et al. Perioperative outcomes and oncologic efficacy from a pilot prospective randomized clinical trial of open versus robotic assisted radical cystectomy. J Urol 2013; 189:474.</a></li><li><a class="nounderline abstract_t">Bochner BH, Sjoberg DD, Laudone VP, Memorial Sloan Kettering Cancer Center Bladder Cancer Surgical Trials Group. A randomized trial of robot-assisted laparoscopic radical cystectomy. N Engl J Med 2014; 371:389.</a></li><li><a class="nounderline abstract_t">Bochner BH, Dalbagni G, Sjoberg DD, et al. Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. Eur Urol 2015; 67:1042.</a></li><li><a class="nounderline abstract_t">Parekh DJ, Reis IM, Castle EP, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet 2018; 391:2525.</a></li><li><a class="nounderline abstract_t">Sathianathen NJ, Kalapara A, Frydenberg M, et al. Robotic Assisted Radical Cystectomy vs Open Radical Cystectomy: Systematic Review and Meta-Analysis. J Urol 2019; 201:715.</a></li><li><a class="nounderline abstract_t">Rai BP, Bondad J, Vasdev N, et al. Robotic versus open radical cystectomy for bladder cancer in adults. Cochrane Database Syst Rev 2019; 4:CD011903.</a></li><li><a class="nounderline abstract_t">Mastroianni R, Ferriero M, Tuderti G, et al. Open Radical Cystectomy versus Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Early Outcomes of a Single-Center Randomized Controlled Trial. J Urol 2022; 207:982.</a></li><li><a class="nounderline abstract_t">Catto JWF, Khetrapal P, Ricciardi F, et al. Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial. JAMA 2022; 327:2092.</a></li><li><a class="nounderline abstract_t">Ahmed K, Khan SA, Hayn MH, et al. Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol 2014; 65:340.</a></li><li><a class="nounderline abstract_t">Zhang JH, Ericson KJ, Thomas LJ, et al. Large Single Institution Comparison of Perioperative Outcomes and Complications of Open Radical Cystectomy, Intracorporeal Robot-Assisted Radical Cystectomy and Robotic Extracorporeal Approach. J Urol 2020; 203:512.</a></li><li><a class="nounderline abstract_t">Mmeje CO, Martin AD, Nunez-Nateras R, et al. Cost analysis of open radical cystectomy versus robot-assisted radical cystectomy. Curr Urol Rep 2013; 14:26.</a></li><li><a class="nounderline abstract_t">Yu HY, Hevelone ND, Lipsitz SR, et al. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol 2012; 61:1239.</a></li><li><a class="nounderline abstract_t">Martin AD, Nunez RN, Castle EP. Robot-assisted radical cystectomy versus open radical cystectomy: a complete cost analysis. Urology 2011; 77:621.</a></li><li><a class="nounderline abstract_t">Lee R, Ng CK, Shariat SF, et al. The economics of robotic cystectomy: cost comparison of open versus robotic cystectomy. BJU Int 2011; 108:1886.</a></li><li><a class="nounderline abstract_t">Leow JJ, Reese SW, Jiang W, et al. Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur Urol 2014; 66:569.</a></li><li><a class="nounderline abstract_t">Chade DC, Laudone VP, Bochner BH, Parra RO. Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approaches. J Urol 2010; 183:862.</a></li><li><a class="nounderline abstract_t">Nepple KG, Strope SA, Grubb RL 3rd, Kibel AS. Early oncologic outcomes of robotic vs. open radical cystectomy for urothelial cancer. Urol Oncol 2013; 31:894.</a></li><li><a class="nounderline abstract_t">Martin AD, Nunez RN, Pacelli A, et al. Robot-assisted radical cystectomy: intermediate survival results at a mean follow-up of 25 months. BJU Int 2010; 105:1706.</a></li><li><a class="nounderline abstract_t">Kauffman EC, Ng CK, Lee MM, et al. Early oncological outcomes for bladder urothelial carcinoma patients treated with robotic-assisted radical cystectomy. BJU Int 2011; 107:628.</a></li><li><a class="nounderline abstract_t">Raza SJ, Wilson T, Peabody JO, et al. Long-term oncologic outcomes following robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol 2015; 68:721.</a></li><li><a class="nounderline abstract_t">Faraj KS, Abdul-Muhsin HM, Rose KM, et al. Robot Assisted Radical Cystectomy vs Open Radical Cystectomy: Over 10 years of the Mayo Clinic Experience. Urol Oncol 2019; 37:862.</a></li><li><a class="nounderline abstract_t">Bochner BH, Dalbagni G, Marzouk KH, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol 2018; 74:465.</a></li><li><a class="nounderline abstract_t">Khan MS, Gan C, Ahmed K, et al. A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL). Eur Urol 2016; 69:613.</a></li><li><a class="nounderline abstract_t">Khan MS, Omar K, Ahmed K, et al. Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL). Eur Urol 2020; 77:110.</a></li></ol></div><div id="topicVersionRevision">Topic 2974 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28456635" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34127436" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32360052" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28495555" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Oncological and functional outcomes of sexual function-preserving cystectomy compared with standard radical cystectomy in men: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25066875" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prostate capsule sparing versus nerve sparing radical cystectomy for bladder cancer: results of a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577131" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fifteen-year single-centre experience with three different surgical procedures of nerve-sparing cystectomy in selected organ-confined bladder cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558643" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15371833" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Attempted nerve sparing surgery and age have a significant effect on urinary continence and erectile function after radical cystoprostatectomy and ileal orthotopic bladder substitution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15491700" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sexual function after male radical cystectomy in a sexually active population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33872050" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28220653" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28220653" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30104615" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pelvic lymph node dissection during radical cystectomy for muscle-invasive bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25074764" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30337060" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1404624" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Laparoscopic cystectomy: initial report on a new treatment for the retained bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18068447" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Perioperative outcomes with laparoscopic radical cystectomy: "pure laparoscopic" and "open-assisted laparoscopic" approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33552567" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Perioperative outcomes of open vs. robotic radical cystectomy: a nationwide comparative analysis (2008-2014).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34994657" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28336308" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Robotic Intracorporeal Continent Cutaneous Diversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366325" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Radical cystectomy in the octogenarian.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15912515" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17041887" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11956429" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Analysis of early complications after radical cystectomy: results of a collaborative care pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12478113" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25560798" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33457280" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Radical cystectomy: a review of techniques, developments and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28768530" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Complications and health-related quality of life after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis of four RCTs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23107013" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Peri-operative morbidity and mortality related to radical cystectomy: a multi-institutional retrospective study in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24844275" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Urinary bladder cancer treated with radical cystectomy: perioperative parameters and early complications prospectively registered in a national population-based database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18675501" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15204405" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Early and late treatment-related morbidity following radical cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12586807" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16600721" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cancer specific outcomes in patients with pT0 disease following radical cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21812902" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Factors influencing post-recurrence survival in bladder cancer following radical cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157016" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16813874" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17085118" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19942232" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20643448" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15199091" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Surgical factors influence bladder cancer outcomes: a cooperative group report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27791991" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Impact of surgical margin status on the outcome of bladder cancer treated by radical cystectomy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18383515" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18085612" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hospital lymph node counts and survival after radical cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25582930" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16952631" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18485042" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20067452" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800327" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981105" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981102" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19616250" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : p53 predictive value for pT1-2 N0 disease at radical cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25200806" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447418" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620494" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Generation of a concise gene panel for outcome prediction in urinary bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18253738" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Guidelines for development of diagnostic markers in bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34266740" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25171129" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment and outcomes of urethral recurrence of urinary bladder cancer in women after radical cystectomy and orthotopic neobladder: a series of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280556" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Urethral recurrence in a woman after continent orthotopic urinary diversion for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19853987" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23017529" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Perioperative outcomes and oncologic efficacy from a pilot prospective randomized clinical trial of open versus robotic assisted radical cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25054732" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A randomized trial of robot-assisted laparoscopic radical cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25496767" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29976469" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30321551" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Robotic Assisted Radical Cystectomy vs Open Radical Cystectomy: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31016718" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Robotic versus open radical cystectomy for bladder cancer in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34986007" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Open Radical Cystectomy versus Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Early Outcomes of a Single-Center Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35569079" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24183419" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31580189" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Large Single Institution Comparison of Perioperative Outcomes and Complications of Open Radical Cystectomy, Intracorporeal Robot-Assisted Radical Cystectomy and Robotic Extracorporeal Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23184624" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cost analysis of open radical cystectomy versus robot-assisted radical cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22482778" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21122900" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Robot-assisted radical cystectomy versus open radical cystectomy: a complete cost analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21501370" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The economics of robotic cystectomy: cost comparison of open versus robotic cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24491306" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083269" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21803615" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Early oncologic outcomes of robotic vs. open radical cystectomy for urothelial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903170" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Robot-assisted radical cystectomy: intermediate survival results at a mean follow-up of 25 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20883479" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Early oncological outcomes for bladder urothelial carcinoma patients treated with robotic-assisted radical cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25985883" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Long-term oncologic outcomes following robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31526651" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Robot Assisted Radical Cystectomy vs Open Radical Cystectomy: Over 10 years of the Mayo Clinic Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29784190" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26272237" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31740072" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
